Analysis of information sources in references of the Wikipedia article "Dimethyltryptamine" in English language version.
Last modified:
After the elaboration of sufficiently selective and quantitative procedures, which are discussed elsewhere, we were able to study the occurrence of tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-hydroxytryptamine in normal human blood and urine. [...] In 11 of 37 probands N,N-dimethyltryptamine was demonstrated in blood (...). In the urine 42.95 ± 8.6 μg of dimethyltryptamine/24 h were excreted.
According to DMT researcher Josie Kins, whom I interviewed for this book: [...] However, when I interviewed Josie Kins and asked her about this, she replied: I'm very much a materialist, despite all the psychedelics I've tried. In fact, the more I've tripped, the more certain I've become that these things are produced by the mind. That doesn't reduce the significance of it for me. [...]
The observation that tolerance to LSD does not confer cross tolerance to several of DMT's autonomic effects suggests that these N-disubstituted compounds may differ in some respects from LSD. The duration of action of DMT is less than that of LSD. Further, we have not been able to demonstrate tachyphylaxis to the actions of tryptamine in the dog (MARTIN and EADES, 1972). Tryptamine's duration of action is less than that of DMT. It is possible that a long duration of action is a necessary attribute of LSD-like hallucinogens for them to effectively induce tolerance (see Subsect. E.III).
Lengthening of the side chain of DMT by a single methylene group produces N,N-dimethylhomotryptamine (DMHT; 76, R = H, n = 3). which produced hyperthermia when administered to rabbits (7,232) but was found to be inactive in man (235). Intravenous administration of 5 and 10 mg and intramuscular injection of 20 to 70 mg DMHT was without psychologic effect in 10 human subjects (235). Additional studies on DMHT homologs (i.e., 76, n = 4–10) did not show any interesting activity (7,232).
[...] all are apparently orally active except for DMT itself, which is orally inactive in doses exceeding 1,000 mg.
The observation that tolerance to LSD does not confer cross tolerance to several of DMT's autonomic effects suggests that these N-disubstituted compounds may differ in some respects from LSD. The duration of action of DMT is less than that of LSD. Further, we have not been able to demonstrate tachyphylaxis to the actions of tryptamine in the dog (MARTIN and EADES, 1972). Tryptamine's duration of action is less than that of DMT. It is possible that a long duration of action is a necessary attribute of LSD-like hallucinogens for them to effectively induce tolerance (see Subsect. E.III).
Parent DMT and 5-MeO−DMT suffer from inherent pharmacokinetic limitations: DMT has an ultrashort half-life (t1/2 = 8−13 min in mice) and is orally inactive without MAOI coadministration, while 5-MeO−DMT also requires MAOI to achieve meaningful oral exposure. To overcome these barriers, Terran Biosciences has developed proprietary prodrugs designed for single oral dosing that bypass first-pass metabolism and subsequently potentially improve CNS delivery after bioconversion (WO2023283364A2).50 Preclinical data demonstrate the success of this approach: oral administration of a DMT prodrug (compound Exp. 2−17, 10 mg/kg) in rats achieved a t1/2 of1.24 h[10.3 h] for DMT, whereas parent DMT given orally is essentially inactive without MAOI coadministration. Similarly, a 5-MeO−DMT prodrug (Exp. 2− 19, 10 mg/kg) yielded a Cmax of 106 ng/mL, and a t1/2 of 2.02 h for 5-MeO−DMT.50
In addition to psilocin, DMT and 5-MeO-DMT have been made into prodrugs despite lacking the 4-hydroxyl group attachment point. [...] In another approach, the dimethylamino group of DMT or 5-MeO-DMT has been used to generate betaine-like prodrugs of these classic psychedelics (e.g., see N-phosphonooxymethyl prodrugs of DMT and 5-MeO-DMT in Table 3 (Khan et al., 2024)).
After the elaboration of sufficiently selective and quantitative procedures, which are discussed elsewhere, we were able to study the occurrence of tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-hydroxytryptamine in normal human blood and urine. [...] In 11 of 37 probands N,N-dimethyltryptamine was demonstrated in blood (...). In the urine 42.95 ± 8.6 μg of dimethyltryptamine/24 h were excreted.
During the first two years of the Harvard Psychedelic Research Project rumors circulated about a "powerful" psychedelic agent called dimethyltryptamine: DMT. The effect of this substance was supposed to last for less than an hour and to produce shattering, terrorizing effects. It was alleged to be the nuclear bomb of the psychedelic family.
[Dave Nichols:] Yeah, the most logical thing would be is that they're inventions from your unconscious. They're representations of something that theoretically, I guess if you took a psychedelic and you queried one of these entities, you could say, who are you to it? Or what do you want? And they might just dissolve, or they might say. Might tell you something about yourself that you had been wondering. But I think you're right. I mean, the most logical scientific explanation is that they're products of your unconscious that are popped up by these amazing effects of psychedelics.
Lengthening of the side chain of DMT by a single methylene group produces N,N-dimethylhomotryptamine (DMHT; 76, R = H, n = 3). which produced hyperthermia when administered to rabbits (7,232) but was found to be inactive in man (235). Intravenous administration of 5 and 10 mg and intramuscular injection of 20 to 70 mg DMHT was without psychologic effect in 10 human subjects (235). Additional studies on DMHT homologs (i.e., 76, n = 4–10) did not show any interesting activity (7,232).
[...] all are apparently orally active except for DMT itself, which is orally inactive in doses exceeding 1,000 mg.
Parent DMT and 5-MeO−DMT suffer from inherent pharmacokinetic limitations: DMT has an ultrashort half-life (t1/2 = 8−13 min in mice) and is orally inactive without MAOI coadministration, while 5-MeO−DMT also requires MAOI to achieve meaningful oral exposure. To overcome these barriers, Terran Biosciences has developed proprietary prodrugs designed for single oral dosing that bypass first-pass metabolism and subsequently potentially improve CNS delivery after bioconversion (WO2023283364A2).50 Preclinical data demonstrate the success of this approach: oral administration of a DMT prodrug (compound Exp. 2−17, 10 mg/kg) in rats achieved a t1/2 of1.24 h[10.3 h] for DMT, whereas parent DMT given orally is essentially inactive without MAOI coadministration. Similarly, a 5-MeO−DMT prodrug (Exp. 2− 19, 10 mg/kg) yielded a Cmax of 106 ng/mL, and a t1/2 of 2.02 h for 5-MeO−DMT.50
In addition to psilocin, DMT and 5-MeO-DMT have been made into prodrugs despite lacking the 4-hydroxyl group attachment point. [...] In another approach, the dimethylamino group of DMT or 5-MeO-DMT has been used to generate betaine-like prodrugs of these classic psychedelics (e.g., see N-phosphonooxymethyl prodrugs of DMT and 5-MeO-DMT in Table 3 (Khan et al., 2024)).
After the elaboration of sufficiently selective and quantitative procedures, which are discussed elsewhere, we were able to study the occurrence of tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-hydroxytryptamine in normal human blood and urine. [...] In 11 of 37 probands N,N-dimethyltryptamine was demonstrated in blood (...). In the urine 42.95 ± 8.6 μg of dimethyltryptamine/24 h were excreted.
Parent DMT and 5-MeO−DMT suffer from inherent pharmacokinetic limitations: DMT has an ultrashort half-life (t1/2 = 8−13 min in mice) and is orally inactive without MAOI coadministration, while 5-MeO−DMT also requires MAOI to achieve meaningful oral exposure. To overcome these barriers, Terran Biosciences has developed proprietary prodrugs designed for single oral dosing that bypass first-pass metabolism and subsequently potentially improve CNS delivery after bioconversion (WO2023283364A2).50 Preclinical data demonstrate the success of this approach: oral administration of a DMT prodrug (compound Exp. 2−17, 10 mg/kg) in rats achieved a t1/2 of1.24 h[10.3 h] for DMT, whereas parent DMT given orally is essentially inactive without MAOI coadministration. Similarly, a 5-MeO−DMT prodrug (Exp. 2− 19, 10 mg/kg) yielded a Cmax of 106 ng/mL, and a t1/2 of 2.02 h for 5-MeO−DMT.50
"When you look at molecules like psilocybin, lysergic acid diethylamide (LSD) or dimethyltryptamine (DMT), they are all almost identical to approved headache medications in terms of their chemical structure and pharmacological profile," Schindler states.
Son of central district judge arrested for allegedly importing DMT – LSD like drug – from Holland. [...] The suspect denies the allegations against him and claims he did not know the substance was on the list of illegal drugs.
{{cite book}}: CS1 maint: bot: original URL status unknown (link){{cite magazine}}: CS1 maint: deprecated archival service (link){{cite book}}: CS1 maint: bot: original URL status unknown (link)Lengthening of the side chain of DMT by a single methylene group produces N,N-dimethylhomotryptamine (DMHT; 76, R = H, n = 3). which produced hyperthermia when administered to rabbits (7,232) but was found to be inactive in man (235). Intravenous administration of 5 and 10 mg and intramuscular injection of 20 to 70 mg DMHT was without psychologic effect in 10 human subjects (235). Additional studies on DMHT homologs (i.e., 76, n = 4–10) did not show any interesting activity (7,232).
Son of central district judge arrested for allegedly importing DMT – LSD like drug – from Holland. [...] The suspect denies the allegations against him and claims he did not know the substance was on the list of illegal drugs.